Life‑sciences using video to woo directors
Bay Area life‑sciences firms are leveraging lab‑to‑market video case studies to attract funding and board talent, using digital storytelling as a recruitment tool for Series B–D companies reported. That means candidates who can speak to commercialization and capital strategy are more visible to growth‑stage boards.
iStudios istudiosmedia.com a focused playbook on Mar 13, 2026 outlining documentary‑style lab‑to‑market films with 4K cinematography and motion‑graphics to surface commercial milestones for Series B–D companies. The Bay Area life‑sciences cluster produced $142.7 billion in economic output and supported 328,000 jobs in 2023, a scale that concentrates both investor interest and competition for experienced directors biocom.org. Regional venture activity has rebounded: VC funding in the Bay Area rose nearly 15% from the end of 2023 to 2024, with Nuvig Therapeutics’ $161 million Series B highlighted as a top late‑stage round savills.com. Board composition is in flux: PwC’s recent survey found only about one‑third of executives say their boards have the right mix of skills and 55% of directors believe at least one director should be replaced, signaling heightened demand for refreshment and specialist experience pwc.com. Recruiters and governance advisers are formalizing skill maps—73% of boards used skills matrices in recent director disclosures—and industry/regulatory/commercialization expertise ranks highly in executive priorities for board refreshment directorsandboards.com and corpgov.law.harvard.edu. Production teams are pitching videos as reusable IP: iStudios recommends a “capture once, distribute everywhere” pipeline and counsels early legal vetting for biosafety and IP, while deal advisers expect strategic M&A and capital deployment to accelerate in 2026—increasing the value of directors with commercialization and capital strategy track records istudiosmedia.com and pwc.com.
